"Cytokine Storm", Not Only in COVID-19 Patients. Mini-review

Overview

Journal Immunol Lett

Specialty Allergy & Immunology

Date 2020 Oct 2

PMID 33007369

Citations 16

Authors

Norbert Lukan

Affiliations

Soon will be listed here.

Abstract

Cytokine storm is a form of uncontrolled systemic inflammatory reaction activated by a variety of factors and leading to a harmful homeostatic process, even to patient's death. Triggers that start the reaction are infection, systemic diseases and rarely anaphylaxis. Cytokine storm is frequently mentioned in connection to medical interventions such as transplantation or administration of drugs. Presented mini-review would like to show current possibilities how to fight or even stop such a life-threatening, immune-mediated process in order to save lives, not only in COVID-19 patients. Early identification of rising state and multilevel course of treatment is imperative. The most widely used molecule for systemic treatment remains tocilizumab. Except for anti IL-6 treatment, contemporary research opens the possibilities for combination of pharmaceutical, non-pharmaceutical and adjunctive treatment in a successful fight with consequences of cytokine storm. Further work is needed to discover the exact signaling pathways that lead to cytokine storm and to determine how these effector molecules and/or combination of processes can help to resolve this frequently fatal episode of inﬂammation. It is a huge need for all scientists and clinicians to establish a physiological rational for new therapeutic targets that might lead to more personalized medicine approaches.

Citing Articles

Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches.

Paranga T, Mitu I, Pavel-Tanasa M, Rosu M, Miftode I, Constantinescu D Int J Mol Sci. 2024; 25(21).

PMID: 39518964 PMC: 11547016. DOI: 10.3390/ijms252111411.

Vaping-associated illness: a reassessment.

Schiffman J Int J Emerg Med. 2024; 17(1):107.

PMID: 39223452 PMC: 11367922. DOI: 10.1186/s12245-024-00692-4.

The critical impacts of cytokine storms in respiratory disorders.

Riyaz Tramboo S, Elkhalifa A, Quibtiya S, Ali S, Shah N, Taifa S Heliyon. 2024; 10(9):e29769.

PMID: 38694122 PMC: 11058722. DOI: 10.1016/j.heliyon.2024.e29769.

SNP (A > G - rs13057211) but not GT(n) polymorphism in HMOX-1 promotor gene is associated with COVID-19 mortality.

Fares K, El-Deeb M, Elsammak O, Ouf A, Saeed H, Baess A BMC Pulm Med. 2023; 23(1):514.

PMID: 38129860 PMC: 10734135. DOI: 10.1186/s12890-023-02785-x.

IKK2/NFkB signaling controls lung resident CD8 T cell memory during influenza infection.

Pritzl C, Luera D, Knudson K, Quaney M, Calcutt M, Daniels M Nat Commun. 2023; 14(1):4331.

PMID: 37468506 PMC: 10356942. DOI: 10.1038/s41467-023-40107-1.

References

Wing M, Moreau T, Greenwood J, Smith R, Hale G, Isaacs J . Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest. 1996; 98(12):2819-26. PMC: 507749. DOI: 10.1172/JCI119110. View

Aikawa N, Fujishima S, Shinozawa Y, Hori S . [Cytokine-mediated biological response to severe infections in surgical patients]. Nihon Geka Gakkai Zasshi. 1996; 97(12):1054-9. View

Cecrdlova E, Petrickova K, Kolesar L, Petricek M, Sekerkova A, Svachova V . Manumycin A downregulates release of proinflammatory cytokines from TNF alpha stimulated human monocytes. Immunol Lett. 2015; 169:8-14. DOI: 10.1016/j.imlet.2015.11.010. View

Freeman C, Morschhauser F, Sehn L, Dixon M, Houghton R, Lamy T . Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions. Blood. 2015; 126(24):2646-9. PMC: 4671111. DOI: 10.1182/blood-2015-09-670802. View

Schulert G, Grom A . Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2014; 66:145-59. PMC: 5846123. DOI: 10.1146/annurev-med-061813-012806. View

Ahmed A, Merrill S, Alsawah F, Bockenstedt P, Campagnaro E, Devata S . Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. PMC: 8054981. DOI: 10.1016/S2352-3026(19)30156-5. View

Picard M, Galvao V . Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2017; 5(3):600-609. DOI: 10.1016/j.jaip.2016.12.001. View

Chung F . Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediators Inflamm. 2001; 10(2):51-9. PMC: 1781697. DOI: 10.1080/09629350120054518. View

Han D, Wei T, Zhang S, Wang M, Tian H, Cheng J . The therapeutic effects of sodium cromoglycate against influenza A virus H5N1 in mice. Influenza Other Respir Viruses. 2015; 10(1):57-66. PMC: 4687497. DOI: 10.1111/irv.12334. View

10.

Federici S, Martini A, Gattorno M . The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Front Immunol. 2013; 4:351. PMC: 3814084. DOI: 10.3389/fimmu.2013.00351. View

11.

Vegh P, ERDOS E, Balogh E, JANOSSY T, KOVATS T . A comparative study on the local inflammatory and immunosuppressive activities of anti-mouse anti-lymphocyte sera. Clin Exp Immunol. 1975; 19(2):387-91. PMC: 1538086. View

12.

Liu Q, Zhou Y, Yang Z . The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol. 2015; 13(1):3-10. PMC: 4711683. DOI: 10.1038/cmi.2015.74. View

13.

Sandilands G, Wilson M, Huser C, Jolly L, Sands W, McSharry C . Were monocytes responsible for initiating the cytokine storm in the TGN1412 clinical trial tragedy?. Clin Exp Immunol. 2010; 162(3):516-27. PMC: 3026555. DOI: 10.1111/j.1365-2249.2010.04264.x. View

14.

Thomsen H, Rittig N, Johannsen M, Moller A, Jorgensen J, Jessen N . Effects of 3-hydroxybutyrate and free fatty acids on muscle protein kinetics and signaling during LPS-induced inflammation in humans: anticatabolic impact of ketone bodies. Am J Clin Nutr. 2018; 108(4):857-867. DOI: 10.1093/ajcn/nqy170. View

15.

Ciavarella C, Motta I, Valente S, Pasquinelli G . Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease. Molecules. 2020; 25(9). PMC: 7248959. DOI: 10.3390/molecules25092076. View

16.

Feng X, Scheinberg P, Biancotto A, Rios O, Donaldson S, Wu C . In vivo effects of horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica. 2014; 99(9):1433-40. PMC: 4562531. DOI: 10.3324/haematol.2014.106542. View

17.

Das R, Guan P, Sprague L, Verbist K, Tedrick P, An Q . Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood. 2016; 127(13):1666-75. PMC: 4817310. DOI: 10.1182/blood-2015-12-684399. View

18.

Schroeder M, Khoury H, Jagasia M, Ali H, Schiller G, Staser K . A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease. Blood Adv. 2020; 4(8):1656-1669. PMC: 7189299. DOI: 10.1182/bloodadvances.2019001043. View

19.

Hoiland R, Stukas S, Cooper J, Thiara S, Chen L, Biggs C . Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome. Br J Haematol. 2020; 190(3):e150-e154. PMC: 7361645. DOI: 10.1111/bjh.16961. View

20.

Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler H, Schlosser H, Schlaak M . Cytokine release syndrome. J Immunother Cancer. 2018; 6(1):56. PMC: 6003181. DOI: 10.1186/s40425-018-0343-9. View